![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, December 28, 2014 7:42:43 AM
I spoke to an Analyst at one of the leading investment boutique firms in NYC (who covers small bio's). He routinely speaks to Gerald from time to time; he reminded me that the ESS trial start up has unique attributes because its not a drug compound that carries a lot of risk. Most importantly, he said once the trial starts up; the market cap alone should be increased by at least $150-$180mm (and Wall street will heed notice once the firm is Up listed).
Overall, the incremental dilution (more recent) is minor in relation to the quality assets that Gerald (and management) have been acquiring lately and of whats most important is the true underlying valuation (so watch what happens to the Market cap in 2015....you will be pleasantly surprised).
Note: Sorry Solantey; you last chance to acquire the PPS much cheaper are behind you. Just recognize that you cant stop a tidal wave that's starting to begin and in motion; just jump on and go for the ride.
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM